苯并[h]喹唑啉-4(3H)-酮 | 506418-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 苯并[h]喹唑啉-4(3H)-酮
• 英文名称: 3,4-dihydrobenzo[h]quinazolin-4-one
• 英文别名: benzo[h]quinazolin-4(3H)-one；samoquasine A；Benzo[h]quinazolin-4(1H)-one；3H-benzo[h]quinazolin-4-one
• CAS: 506418-75-3
• 化学式: C₁₂H₈N₂O
• 分子量: 196.208
• InChiKey: BJVYARVTSUNBMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  苯并[h]喹唑啉-4(3H)-酮 在 三乙胺 、 三氯氧磷 作用下， 反应 3.0h， 以63%的产率得到4-chlorobenzo[h]quinazoline
  参考文献：
  名称：

  基于喹唑啉的多酪氨酸激酶抑制剂：合成，建模，抗肿瘤和抗血管生成特性

  摘要：

  在这项工作中，报道了一些在喹唑啉支架和苯胺部分带有修饰的新型苯胺喹唑啉衍生物的合成和生物学评估。初步的细胞毒性研究确定了三种衍生物，它们是最有效的化合物，这些衍生物带有稠合在喹唑啉部分和联苯氨基取代基作为苯胺部分的双加氧环。进一步的研究表明，这些化合物通过抑制受体和非受体TK，在多种人类肿瘤细胞系中均表现出抗增殖活性。此外，带有二氧戊环核的化合物也能够在体内抑制肿瘤生长。这些化合物进入激酶结构域的分子模型表明，苯基基团允许与目标蛋白质具有良好的相互作用能：该特征在6,7位上被稠合的双加氧环所支持，而自由旋转功能不允许正确放置分子，从而削弱了抑制效力。最后，联苯氨基衍生物在非细胞毒性浓度下，在体外和体内试验中均作为抗血管生成剂。

  DOI：

  10.1016/j.ejmech.2013.06.057
• 作为产物：
  描述：

  硝基萘 在 氢氧化钾 、 sodium hydroxide 、 氰乙酸乙酯 作用下， 以 乙醇 为溶剂， 反应 40.17h， 生成 苯并[h]喹唑啉-4(3H)-酮
  参考文献：
  名称：

  Total synthesis of 3,4-dihydrobenzo[h]quinazolin-4-one and structure elucidation of perlolidine and samoquasine A

  摘要：

  The total synthesis of 3,4-dihydrobenzo[h]quinazolin-4-one is described. Based on the spectral data and chemical evidence, the structures of 3,4-dihydrobenzo[h]quinazolin-4-one, perlolidine, and samoquasine A are not the same. A structure for samoquasine A is suggested. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(02)02577-7

文献信息

• Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device
  申请人：Semiconductor Energy Laboratory Co., Ltd.

  公开号：US09444059B2

  公开（公告）日：2016-09-13

  A novel substance capable of emitting phosphorescence is provided. An organometallic complex represented by General Fomulae (G3) or (G5). In the formulae, M represents iridium, platinum, palladium, or rhodium, R1 represents a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms, or a substituted or unsubstituted aryl group having 6 to 10 carbon atoms, and R2 to R7 separately represent hydrogen or a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms.

  提供了一种能够发射磷光的新颖物质。一种由一般式（G3）或（G5）表示的有机金属配合物。在这些式子中，M代表铱、铂、钯或铑，R1代表具有1至6个碳原子的取代或未取代的烷基基团，或具有6至10个碳原子的取代或未取代的芳基基团，R2至R7分别代表氢或具有1至6个碳原子的取代或未取代的烷基基团。
• An Expedient Synthesis of Benzo[<i>h</i>]quinazolin-4(3<i>H</i>)-one: Structure of Samoquasine A Revisited
  作者：Manas Chakrabarty、Sandipan Sarkar、Yoshihiro Harigaya

  DOI：10.1055/s-2003-42409

  日期：——

  An expedient four-step synthesis of benzo[h]quinazolin4(3H)-one (1) starting from 1-tetralone is reported. The claimed identity of samoquasine A with perlolidine (4) has been discussed in the light of the present synthesis.

  报道了从 1-四氢萘酮开始的苯并 [h] 喹唑啉 4(3H)-one (1) 的便捷四步合成。已根据本合成讨论了声称的萨莫夸辛 A 与哌洛啶 (4) 的同一性。
• Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08883810B2

  公开（公告）日：2014-11-11

  The present invention is directed to benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式(I)的苯并喹啉酮化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物治疗M1受体介导的疾病。
• ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150031713A1

  公开（公告）日：2015-01-29

  The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的苯并喹唑啉酮化合物，其为M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，例如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面具有用途。该发明还涉及包含该化合物的制药组合物，以及使用该化合物和组合物治疗由M1受体介导的疾病方面的用途。
• Aryl Methyl Benzoquinazolinone M1 Receptor Positive Allosteric Modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140005182A1

  公开（公告）日：2014-01-02

  The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的苯并喹唑啉酮化合物，它们是M1受体正向变构调节剂，并且对于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍等具有用处。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物治疗M1受体介导的疾病。

表征谱图